47 results
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
10 May 24
Regulation FD Disclosure
7:01am
%), with no correlation of nasal discomfort to pain or irritation Mean VAS pain scores between 5 to 8 out of 100 No irritation based on formal assessment No serious
8-K
EX-99.1
SPRY
ARS Pharmaceuticals Inc
7 Mar 24
Results of Operations and Financial Condition
12:56pm
for efficacy observed even 1 minute after dosing No irritation based on formal assessment PK bracketed by approved products (exposures ≥ IM/SC … the various approved injection devices despite different PK
Risk-benefit assessment of neffy Thomas B. Casale, M.D. Professor of Medicine & Pediatrics
8-K
EX-99.1
0md6u1 3i2vw8vgf05
25 Sep 23
Regulation FD Disclosure
4:17pm
8-K
EX-99.1
qeti6l69ozeks3kf7nvg
16 May 23
Regulation FD Disclosure
4:31pm
8-K
EX-99.1
7q1smxlk6 70qaai6
15 May 23
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
9:03am
8-K
EX-99.1
z4ogwlqvo
9 May 23
Regulation FD Disclosure
9:12am
8-K
EX-99.1
lfkt2zb
6 Dec 22
Regulation FD Disclosure
5:07pm
8-K
EX-2.1
9ec jxu3d
8 Nov 22
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
4:51pm
DEFA14A
ji7o1hgf73bvo
27 Oct 22
Additional proxy soliciting materials
4:15pm
DEFM14A
uxwyax3
6 Oct 22
Proxy related to merger
4:16pm
PRER14A
j396y rof5z
16 Sep 22
Preliminary revised proxy
4:56pm
CORRESP
wizpg4j g0
16 Sep 22
Correspondence with SEC
12:00am